Results 61 to 70 of about 17,658 (223)

Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

BMC Cancer, 2020
Background Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC ...
Hiroshi Imaoka, Masafumi Ikeda, Kosuke Maehara, Kumiko Umemoto, Masato Ozaka, Satoshi Kobayashi, Takeshi Terashima, Hiroto Inoue, Chihiro Sakaguchi, Kunihiro Tsuji, Kazuhiko Shioji, Keiya Okamura, Yasuyuki Kawamoto, Rei Suzuki, Hirofumi Shirakawa, Hiroaki Nagano, Makoto Ueno, Chigusa Morizane, Junji Furuse   +18 more
doaj   +1 more source

Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon‐Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Carbon‐ion radiotherapy (CIRT) provides superior dose distribution and higher biological effectiveness than conventional X‐ray radiotherapy and has emerged as a promising component of multidisciplinary treatment for advanced pancreatic ductal adenocarcinoma (PDAC).
Kenichiro Araki, Norio Kubo, Yuhei Miyasaka, Hayato Ikota, Ryo Muranushi, Mariko Tsukagoshi, Takamichi Igarashi, Masahiko Okamoto, Tatsuya Ohno, Ken Shirabe   +9 more
wiley   +1 more source

Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long‐Term Survival

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy.
Ryosuke Fukushima, Kenichiro Araki, Ryo Muranushi, Kouki Hoshino, Kei Hagiwara, Shunsuke Kawai, Mariko Tsukagoshi, Takamichi Igarashi, Norio Kubo, Ken Shirabe   +9 more
wiley   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Clinical Outcomes of Gemcitabine Plus Nab‐Paclitaxel‐Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (NUPAT‐05): A Prospective, Single‐Arm, Phase II Study

International Journal of Cancer, EarlyView.
ABSTRACT Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a Phase I trial of CRT with gemcitabine plus nab‐paclitaxel (GnP) and established the recommended dose.
Hironori Yamada, Haruyoshi Tanaka, Suguru Yamada, Hideki Takami, Masamichi Hayashi, Nobuhiko Nakagawa, Keisuke Kurimoto, Yoshikuni Inokawa, Nobuyuki Watanabe, Takuya Ishikawa, Masayuki Okumura, Hiroshi Ogawa, Masahiko Ando, Osamu Maeda, Junpei Yamaguchi, Shinji Naganawa, Hiroki Kawashima, Tsutomu Fujii, Yukihiro Yokoyama, Tomoki Ebata, Mitsuro Kanda   +20 more
wiley   +1 more source

Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real‐World Population

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction The PRODIGE 24/CCTG PA.6‐ trial has shown an overall survival (OS) up to 55 months in patients treated with (modified) 5‐fluorouracil, leucovorin, irinotecan and oxaliplatin ((m)FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). The applicability of these results to a real‐world patient population
N. C. Biesma, G. A. Cirkel, N. Haj Mohammad, M. Los, R. C. Verdonk, I. Q. Molenaar, L. A. Daamen, H. C. van Santvoort   +7 more
wiley   +1 more source

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer

OncoTargets and Therapy, 2014
Advanced pancreatic adenocarcinoma is a deadly disease and is considered incurable. For the past two decades, gemcitabine remained the major chemotherapeutic drug with modest clinical benefit. Many chemotherapy and targeted agents were combined with gemcitabine but failed to demonstrate improvement in pancreatic cancer (PC) survival.
Al-Hajeili,Marwan, Azmi,Asfar, Choi,Minsig   +2 more
openaire   +4 more sources

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice

Journal of Cancer Research and Therapeutics, 2018
Pancreatic cancer in a common tumor in our country for which there are various treatment alternatives.Evaluate the effectiveness and safety of nab-paclitaxel and gemcitabine in everyday clinical practice.Observational, retrospective study at a tertiary university hospital.We included patients diagnosed of metastatic or locally advanced pancreatic ...
Cristina, Casanova-Martinez, Elena Yaiza, Romero-Ventosa, Sonia, González-Costas, Cecilia, Arroyo-Conde, Guadalupe, Piñeiro-Corrales   +4 more
openaire   +2 more sources

Baicalein Sensitizes Radioresistant BT549 and MCF7‐R Breast Cancer Cells by Modulating Rac1 Signaling

Phytotherapy Research, EarlyView.
ABSTRACT Radioresistance remains a key barrier in breast cancer (BC) treatment. Baicalein, a flavonoid from Scutellaria baicalensis, has shown potential to enhance radiosensitivity. This study investigates its efficacy and mechanism in radioresistant BC models. Radioresistant BC cell models were established via fractionated irradiation and validated by
Zitong Zhao, Zhangyun Li, Quanzhou Peng, Shuqun Zhang   +3 more
wiley   +1 more source